Stoke Therapeutics upgraded by BofA Securities with a new price target

5/1/23 9:05:07 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

BofA Securities upgraded Stoke Therapeutics from Underperform to Neutral and set a new price target of $12.00 from $9.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$STOK

Date	Price Target	Rating	Analyst
12/20/2024	$24.00	Buy	Chardan Capital Markets
10/14/2024	$18.00	Outperform	Leerink Partners
3/26/2024		Market Perform → Outperform	TD Cowen
11/20/2023		Neutral	JP Morgan
7/25/2023		Outperform → Market Perform	TD Cowen
5/1/2023	$9.00 → $12.00	Underperform → Neutral	BofA Securities
4/26/2023	$24.00	Buy	Canaccord Genuity
1/6/2023	$22.00 → $9.00	Buy → Underperform	BofA Securities